Efficacy and Safety of Autologous Cytokine-Induced Killer (CIK) Cellular Immunotherapy Combined with Chemotherapy in Non-Small-Cell Carcinoma (NSCLC): A Meta-Analysis.
{"title":"Efficacy and Safety of Autologous Cytokine-Induced Killer (CIK) Cellular Immunotherapy Combined with Chemotherapy in Non-Small-Cell Carcinoma (NSCLC): A Meta-Analysis.","authors":"Cheng Zhong, Haowei Tang, Qun Wang","doi":"10.18502/ijph.v53i8.16277","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To investigate the efficacy and safety of autologous Cytokine-induced killer (CIK) cellular immunotherapy combined with chemotherapy for non-small-cell carcinoma (NSCLC).</p><p><strong>Methods: </strong>The literature related to the efficacy and safety of autologous CIK cellular immunotherapy combined with chemotherapy in NSCLC were collected. The Chinese literature databases were collected from CNKI, Wanfang and Weipu, and the English literature were retrieved from Cochrane Library and PubMed. All literature were retrieved until the year of 2022, and evaluated by its method quality and analyzed by RevMan5.3 software.</p><p><strong>Results: </strong>A Meta-analysis on the 11 included literature showed that the treatment efficacy and disease control rate (DCR) of patients in the observation group were significantly higher than those in the control group (<i>P <</i> 0.05), and significantly increased the levels of CD3+, CD4+, CD4+/CD8+ indexes than the control group (<i>P <</i> 0.05), and the incidence of bone marrow suppression, liver injury and gastrointestinal symptoms were significantly lower than those of the control group (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>Compared with single chemotherapy, CIK combined with chemotherapy in the treatment of patients with NSCLC can improve the efficacy of treatment and DCR, significantly improve their immune function, reduce the incidence of adverse reactions, and is beneficial to the recovery of prognosis.</p>","PeriodicalId":49173,"journal":{"name":"Iranian Journal of Public Health","volume":"53 8","pages":"1722-1735"},"PeriodicalIF":1.3000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11475181/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Public Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18502/ijph.v53i8.16277","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0
Abstract
Background: To investigate the efficacy and safety of autologous Cytokine-induced killer (CIK) cellular immunotherapy combined with chemotherapy for non-small-cell carcinoma (NSCLC).
Methods: The literature related to the efficacy and safety of autologous CIK cellular immunotherapy combined with chemotherapy in NSCLC were collected. The Chinese literature databases were collected from CNKI, Wanfang and Weipu, and the English literature were retrieved from Cochrane Library and PubMed. All literature were retrieved until the year of 2022, and evaluated by its method quality and analyzed by RevMan5.3 software.
Results: A Meta-analysis on the 11 included literature showed that the treatment efficacy and disease control rate (DCR) of patients in the observation group were significantly higher than those in the control group (P < 0.05), and significantly increased the levels of CD3+, CD4+, CD4+/CD8+ indexes than the control group (P < 0.05), and the incidence of bone marrow suppression, liver injury and gastrointestinal symptoms were significantly lower than those of the control group (P < 0.05).
Conclusion: Compared with single chemotherapy, CIK combined with chemotherapy in the treatment of patients with NSCLC can improve the efficacy of treatment and DCR, significantly improve their immune function, reduce the incidence of adverse reactions, and is beneficial to the recovery of prognosis.
期刊介绍：
Iranian Journal of Public Health has been continuously published since 1971, as the only Journal in all health domains, with wide distribution (including WHO in Geneva and Cairo) in two languages (English and Persian). From 2001 issue, the Journal is published only in English language. During the last 41 years more than 2000 scientific research papers, results of health activities, surveys and services, have been published in this Journal. To meet the increasing demand of respected researchers, as of January 2012, the Journal is published monthly. I wish this will assist to promote the level of global knowledge. The main topics that the Journal would welcome are: Bioethics, Disaster and Health, Entomology, Epidemiology, Health and Environment, Health Economics, Health Services, Immunology, Medical Genetics, Mental Health, Microbiology, Nutrition and Food Safety, Occupational Health, Oral Health. We would be very delighted to receive your Original papers, Review Articles, Short communications, Case reports and Scientific Letters to the Editor on the above mentioned research areas.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
